Рembrolizumab as second line therapy for hepatocellular patient

Por I. A. Dzhanyan, V. V. Breder, O. I. Borisova, K. K. Laktionov
Publicado em 2021-12-01

Five-year results of nivolumab for the treatment of non-small cell lung cancer in clinical practice of the N.N. Blokhin Russian Cancer Research Center

Por D. I. Yudin, K. K. Laktionov, K. A. Sarantseva, V. V. Breder, M. S. Ardzinba, E. V. Reutova, O. I. Borisova
Publicado em 2021-08-01

Pseudoprogression in patients on immunotherapy

Por D. I. Yudin, K. K. Laktionov, K. A. Sarantseva, V. V. Breder, E. V. Reutova, O. I. Borisova, M. S. Ardzinba
Publicado em 2019-06-01

Immuno-related endocrinopathy in patients treated with immune checkpoint inhibitors

Por D. I. Yudin, K. K. Laktionov, K. A. Sarantseva, O. I. Borisova, V. V. Breder, E. V. Reutova, M. F. Beloyartseva, S. Yu. Kruteleva, I. A. Dzhanyan
Publicado em 2020-07-01

COMPARATIVE ANALYSIS OF BIOLOGICAL EFFECTS OF SELECTIVE ACTIVATOR OF THE GLUCOCORTICOID RECEPTOR CPDA ON DIFFERENT SUBTYPES OF BREAST CANCER CELL LINES

Por E. M. Zhidkova, K. A. Kuzin, L. R. Tilova, A. V. Savinkova, O. I. Borisova, M. D. Lavrova, V. P. Maximova, K. I. Kirsanov, M. G. Yakubovskaya, E. A. Lesovaya
Publicado em 2017-12-01